“
TL;DR
The central result was that CPS-deficient mutants were attenuated in infection models but could be rescued in complement-deficient hosts.
mBio · 20 authors, 10 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The central result was that CPS-deficient mutants were attenuated in infection models but could be rescued in complement-deficient hosts.
Researchers identified serum-sensitive clinical isolates with defective CPS production. Genetic deletion of the wzy gene, required for CPS biosynthesis, in a serum-resistant isolate rendered it highly sensitive to human serum and attenuated in a mouse pneumonia model, but not in C3-deficient mice, highlighting the role of CPS in evading complement-mediated immunity. Implications point toward CPS as a potential target for future therapeutic or vaccine development against this resistant pathogen.